| Market Cap | 2.18M | P/E | 0.01 | EPS this Y | 98.70% | Ern Qtrly Grth | - |
| Income | -12.82M | Forward P/E | -1.38 | EPS next Y | 39.90% | 50D Avg Chg | -61.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -99.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | 3.00 | Quick Ratio | 1.96 | Shares Outstanding | 1.41M | 52W Low Chg | 13.00% |
| Insider Own | 3.93% | ROA | -47.72% | Shares Float | 1.41M | Beta | 0.34 |
| Inst Own | 1.20% | ROE | -121.82% | Shares Shorted/Prior | 94.57K/9.98K | Price | 2.53 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 624,959 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 597,233 | Change | 1.61% |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
